Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2026

Conditions
Stem Cell Transplant ComplicationsLeukemia, Myeloid, AcuteLeukemia Relapse
Interventions
DRUG

Decitabine

Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11

DRUG

mBU/CY and ATG

Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2

DRUG

mBU/CY

hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3

Trial Locations (1)

100044

RECRUITING

Peking University Institute of Hematology,Beijing, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER